CytRx will present new preclinical data demonstrating that its oral drug candidate arimoclomol improved the functional recovery of rat motor skills damaged by stroke. Stroke was induced in study rats by blocking blood flow to parts of the brain. A subgroup of the study rats were then dosed orally with arimoclomol daily for 28 days. While motor skills declined dramatically in all study rats, those treated with arimoclomol recovered faster and more completely than those untreated.

Mr. Kriegsman commented, “We are encouraged by results from this very early-stage experiment in stroke recovery that indicates arimoclomol may protect the brain from the consequences of trauma, in this case caused by oxygen deprivation. This preclinical data lends further support to our previously-stated belief that arimoclomol may have therapeutic potential in multiple clinical indications.”

A live audio and slide presentation will be available via the Internet by visiting the News & Events section of the company’s Web site at www.cytrx.com. More information about the conference is available at http://www.rodmanandrenshaw.com/Conferences.asp?CID=conf19.

CytRx Corporation (Nasdaq:CYTR), a company biopharmaceutical has coupled in the development and human commercialization therapeutic, today announced that the president and the CEO Steven To Kriegsman and greater vice-president of the barber of the Jack of development of the drug, Ph.D., will render to one Community of investment the presentation to rodman & the conference anniversary of Renshaw the eighth Healthcare the tuesday, 7 November to 9:30 a.m.. Time orients them (6:30 a.m.. Pacific time). The conference is holding to the hotel of the palace to New York City.

CytRx will introduce the new data preclinical that they demonstrate that relative arimoclomol the oral one of the candidate of the drug has improved the recovery works them of the motorie abilities of the rape damaged from the blow. The blow has been induced in the study rapes obstructing the flow of spirit to the parts of the brain. A subgroup of the study rapes then has been dosed orally with the daily paper of arimoclomol for 28 days. While the motorie abilities have declined dramatically in all the rapes of study, those have dealt with the arimoclomol recovered fastly and completely of those it does not deal to you.

About Arimoclomol
Arimoclomol is one of CytRx’s three orally-administered, small molecule compounds. This small molecule drug candidate is believed to function by stimulating a normal cellular protein repair pathway through the activation of “molecular chaperones.” Since damaged proteins called aggregates are thought to play a role in many diseases, CytRx believes that activation of molecular chaperones could have therapeutic efficacy for a broad range of diseases.

In September 2006, CytRx announced that arimoclomol was shown to be safe and well tolerated at all three doses tested in its Phase IIa clinical trial in patients with amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease). The Company plans to enter a Phase IIb clinical trial with arimoclomol in ALS in the first half of next year, subject of U.S. Food and Drug Administration (FDA) approval. The FDA has granted Fast Track designation and Orphan Drug status and the European Commission has granted orphan medicinal product status to arimoclomol for the treatment of ALS.

About CytRx Corporation
CytRx Corporation is a biopharmaceutical research and development company engaged in the development of high-value human therapeutics. The Company owns three clinical-stage compounds based on its small molecule “molecular chaperone” co-induction technology. In September 2006, CytRx announced receipt of $24.5 million in a non-dilutive agreement with the privately-funded ALS Charitable Remainder Trust to fund continued arimoclomol development for the treatment for ALS in return for a one percent royalty from potential worldwide sales of arimoclomol for the treatment of ALS. The Greater Los Angeles Chapter of The ALS Association is the charitable beneficiary of the ALS Charitable Remainder Trust.

CytRx has a broad-based strategic alliance with the University of Massachusetts Medical School to develop novel compounds in the areas of ALS, obesity, type 2 diabetes and cytomegalovirus (CMV) using RNAi technology. The Company has a research program with Massachusetts General Hospital, Harvard University’s teaching hospital, to use RNAi technology to develop a drug for the treatment of ALS. CytRx’s Drug Discovery division, located in Worcester, Massachusetts, focuses on the use of RNAi technologies to develop small molecule and RNAi therapeutics to treat obesity and type 2 diabetes. For more information, visit CytRx’s Web site at www.cytrx.com.